Fast-acting plant-based medicinal compounds and nutritional supplements
Plant-based medicinal compounds or nutritional supplements in various carrier combinations are described. The carriers can include N-acylated fatty amino acids, penetration enhancers, and/or various other beneficial carriers. The plant-based composition/carrier combinations can create administration benefits.
1. A method of providing increased bioavailability of a cannabinoid with an aqueous solubility of less than 0.1 mg/ml in an oral formulation, the method comprising
adding an N-acylated fatty amino acid or salt thereof comprising the formula:
to the oral formulation
wherein X and Z are independently hydrogen, a monovalent cation, a divalent metal cation, or an organic cation, and
wherein the N-acylated fatty amino acid or salt thereof is added in an amount that is one to twenty times the amount of the cannabinoid in the oral formulation, thereby providing increased bioavailability when compared to the same oral formulation without the added N-acylated fatty amino acid or salt thereof.
2. The method of claim 1 , wherein the cannabinoid with an aqueous solubility of less than 0.1 mg/ml comprises tetrahydrocannabinol (THC) and/or cannabidiol (CBD).
3. The method of claim 1 , wherein the cannabinoid with an aqueous solubility of less than 0.1 mg/ml is derived from cannabis.
4. The method of claim 3 , wherein the cannabis is selected from Cannabis sativa, Cannabis ruderalis , and Cannabis indica.
5. The method of claim 1 , wherein the cannabinoid comprises tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinerolic acid, cannabidiolic acid (CBDA), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarinic acid (THCVA) or mixtures thereof.
6. The method of claim 1 , wherein X is selected from: hydrogen; sodium or potassium as the monovalent cation; calcium or magnesium as the divalent metal cation; or tetramethylammonium as the organic cation.
7. The method of claim 1 , wherein Z is selected from: hydrogen; sodium or potassium as the monovalent cation; or calcium or magnesium as the divalent metal cation.
8. The method of claim 1 , wherein the N-acylated fatty amino acid or salt thereof is selected from the group consisting of monosodium-N-salicyloyl-8-aminocaprylate, disodium-N-salicyloyl-8-aminocaprylate, and N-(salicyloyl)-8-aminocaprylic acid.
9. The method of claim 1 , wherein X is sodium and Z is hydrogen.
10. The method of claim 1 , wherein X is hydrogen and Z is hydrogen.
11. The method of claim 1 , wherein X is hydrogen and Z is sodium.
12. The method of claim 1 , wherein X is sodium and Z is sodium.
13. The method of claim 1 , wherein the N-acylated fatty amino acid or salt thereof is added in an amount that is one to ten times the amount of the cannabinoid.
14. The method of claim 1 , wherein the adding comprises adding 100-200 mg of the N-acylated fatty amino acid to the oral formulation.
15. The method of claim 1 , wherein the oral formulation comprises up to 1 gram of the cannabinoid.
16. The method of claim 1 , wherein the oral formulation further comprises flavonoid compounds, terpenes, or terpenoids.
17. The method of claim 1 , wherein the oral formulation further comprises an excipient.
18. The method of claim 17 , wherein the excipient comprises a surfactant, a flavorant, or a sweetener.
19. The method of claim 1 , wherein the oral formulation comprises a solution formulation or a suspension formulation.
20. The method of claim 19 , wherein the solution formulation or the suspension formulation is within a gelcap.